enVVeno Medical Corporation

NasdaqCM:NVNO Stock Report

Market Cap: US$60.5m

enVVeno Medical Balance Sheet Health

Financial Health criteria checks 6/6

enVVeno Medical has a total shareholder equity of $38.4M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $41.0M and $2.6M respectively.

Key information

0%

Debt to equity ratio

US$0

Debt

Interest coverage ration/a
CashUS$39.07m
EquityUS$38.42m
Total liabilitiesUS$2.58m
Total assetsUS$41.00m

Recent financial health updates

Recent updates

Here's Why We're Not Too Worried About enVVeno Medical's (NASDAQ:NVNO) Cash Burn Situation

Jun 26
Here's Why We're Not Too Worried About enVVeno Medical's (NASDAQ:NVNO) Cash Burn Situation

Companies Like enVVeno Medical (NASDAQ:NVNO) Are In A Position To Invest In Growth

Mar 07
Companies Like enVVeno Medical (NASDAQ:NVNO) Are In A Position To Invest In Growth

Will enVVeno Medical (NASDAQ:NVNO) Spend Its Cash Wisely?

Aug 14
Will enVVeno Medical (NASDAQ:NVNO) Spend Its Cash Wisely?

Is enVVeno Medical (NASDAQ:NVNO) In A Good Position To Deliver On Growth Plans?

Apr 22
Is enVVeno Medical (NASDAQ:NVNO) In A Good Position To Deliver On Growth Plans?

We're Not Very Worried About enVVeno Medical's (NASDAQ:NVNO) Cash Burn Rate

Dec 21
We're Not Very Worried About enVVeno Medical's (NASDAQ:NVNO) Cash Burn Rate

enVVeno Medical: Unique Exposure To Venous Treatment Domain

Sep 23

We're Hopeful That enVVeno Medical (NASDAQ:NVNO) Will Use Its Cash Wisely

Aug 23
We're Hopeful That enVVeno Medical (NASDAQ:NVNO) Will Use Its Cash Wisely

enVVeno Medical reports Q2 results

Aug 03

We Think enVVeno Medical (NASDAQ:NVNO) Can Afford To Drive Business Growth

May 10
We Think enVVeno Medical (NASDAQ:NVNO) Can Afford To Drive Business Growth

We're Not Very Worried About enVVeno Medical's (NASDAQ:NVNO) Cash Burn Rate

Jan 25
We're Not Very Worried About enVVeno Medical's (NASDAQ:NVNO) Cash Burn Rate

Hancock Jaffe Laboratories: Developing Nature-Mimetic Bioprosthetics

Sep 08

Hancock Jaffe Laboratories finance chief sheds interim tag

Dec 31

Hancock Jaffe approves 1:25 reverse stock split

Nov 27

Financial Position Analysis

Short Term Liabilities: NVNO's short term assets ($39.5M) exceed its short term liabilities ($1.7M).

Long Term Liabilities: NVNO's short term assets ($39.5M) exceed its long term liabilities ($882.0K).


Debt to Equity History and Analysis

Debt Level: NVNO is debt free.

Reducing Debt: NVNO had no debt 5 years ago.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: NVNO has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: NVNO has sufficient cash runway for 2.1 years if free cash flow continues to reduce at historical rates of 22.5% each year.


Discover healthy companies